Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma

Asher A Chanan Khan, Tariq Islam, Arif Alam, Kena C. Miller, John Gibbs, Maurice Barcos, Myron S. Czuczman, Pamela Paplham, Theresa Hahn, Philip McCarthy

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with α/β HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath®). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.

Original languageEnglish (US)
Pages (from-to)1673-1675
Number of pages3
JournalLeukemia and Lymphoma
Volume45
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Salvage Therapy
T-Cell Lymphoma
Stem Cell Transplantation
Non-Hodgkin's Lymphoma
Stem Cells
Monoclonal Antibodies
Tissue Donors
Lymphocytes
Transplants
Survival
T-Lymphocytes
Recurrence
Drug Therapy
alemtuzumab
Therapeutics

Keywords

  • Alemtuzumab
  • Allogeneic
  • Non-Hodgkin's lymphoma
  • T-cell

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma. / Chanan Khan, Asher A; Islam, Tariq; Alam, Arif; Miller, Kena C.; Gibbs, John; Barcos, Maurice; Czuczman, Myron S.; Paplham, Pamela; Hahn, Theresa; McCarthy, Philip.

In: Leukemia and Lymphoma, Vol. 45, No. 8, 08.2004, p. 1673-1675.

Research output: Contribution to journalArticle

Chanan Khan, Asher A ; Islam, Tariq ; Alam, Arif ; Miller, Kena C. ; Gibbs, John ; Barcos, Maurice ; Czuczman, Myron S. ; Paplham, Pamela ; Hahn, Theresa ; McCarthy, Philip. / Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma. In: Leukemia and Lymphoma. 2004 ; Vol. 45, No. 8. pp. 1673-1675.
@article{a521e0412ffe41ec85595b9eaa743c5b,
title = "Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma",
abstract = "Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with α/β HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath{\circledR}). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.",
keywords = "Alemtuzumab, Allogeneic, Non-Hodgkin's lymphoma, T-cell",
author = "{Chanan Khan}, {Asher A} and Tariq Islam and Arif Alam and Miller, {Kena C.} and John Gibbs and Maurice Barcos and Czuczman, {Myron S.} and Pamela Paplham and Theresa Hahn and Philip McCarthy",
year = "2004",
month = "8",
doi = "10.1080/10428190310001609924",
language = "English (US)",
volume = "45",
pages = "1673--1675",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with α/β hepatosplenic T-cell non-Hodgkin's lymphoma

AU - Chanan Khan, Asher A

AU - Islam, Tariq

AU - Alam, Arif

AU - Miller, Kena C.

AU - Gibbs, John

AU - Barcos, Maurice

AU - Czuczman, Myron S.

AU - Paplham, Pamela

AU - Hahn, Theresa

AU - McCarthy, Philip

PY - 2004/8

Y1 - 2004/8

N2 - Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with α/β HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath®). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.

AB - Hepatosplenic T-cell non-Hodgkin's lymphoma (HSTCL) is a rare, aggressive form of NHL, with a median survival of approximately 8 months. We were able to successfully induce complete remission in a patient with α/β HSTCL who was refractory to multiple prior chemotherapy regimens, using the humanized anti-CD52 monoclonal antibody alemtuzumab (Campath®). Once disease was controlled, the patient was able to undergo allogeneic stem cell transplantation (SCT), which resulted in complete remission. Furthermore, upon relapse, we were able to re-induce complete clinical and molecular remission with donor lymphocyte infusions. At Day 655 (post-SCT), the patient remains in complete remission. These data suggest a potential role for alemtuzumab and allogeneic SCT in the treatment of T-cell NHL.

KW - Alemtuzumab

KW - Allogeneic

KW - Non-Hodgkin's lymphoma

KW - T-cell

UR - http://www.scopus.com/inward/record.url?scp=3042812298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042812298&partnerID=8YFLogxK

U2 - 10.1080/10428190310001609924

DO - 10.1080/10428190310001609924

M3 - Article

VL - 45

SP - 1673

EP - 1675

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 8

ER -